Latest From NeuroSearch AS
Deals and R&D partnerships are coming thick and fast for Takeda in the first few days of the year, with the major Japanese firm unveiling a new tie-up with NsGene to progress direct-delivered cell therapies for Parkinson's disease.
In an interview with Scrip's sister publication "The Pink Sheet", President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva's late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.
In an interview, President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva’s late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.
Atlas Venture and Biogen Idec funded a $17m Series A funding round for Ataxion in an invest-to-own structure that gives Biogen an option to buy the startup company if its pan-ataxia drug candidate successfully completes a Phase I clinical trial.
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- NeuroSearch AS
- Senior Management
- Allan Andersen, CEO
- Contact Info
Phone: (45) 4460 8000
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.